OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if OSI-774 will improve overall survival of
 patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of
 care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor
 receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the
 U.S. Food and Drug Administration (FDA).
-  Clinical diagnosis of stage IIIB or IV non-small cell lung cancer.

 -  Must have evidence of disease (clinical or radiological).

 -  Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any
 side effects and have not had any chemotherapy for at least 21 days.

 -  If the patient has had surgery, the surgery was at least 2 weeks ago.

 -  Patients whose cancer has spread to their brain or central nervous system are
 eligible, providing that they have been on stable dose of steroids for at least 4
 weeks and are free of symptoms.

 -  If the patient received radiation therapy, treatment was at least 4 weeks ago.